Selective targeting of cancer cells using synthetic peptides

Drug Resistance Updates

Volumn 6, Issue 6, 2003, Pages 363-371

  Shadidi, Mohsen ^a   Sioud, Mouldy ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Angiogenesis; Gene therapy; Liposomes; Phage display; Targeting peptides

Indexed keywords

ALANYLISOLEUCYLMETHIONYLALANYLSERYLGLYCYLALANYLTRYTOPHYLLEUCINE; ALANYLLEUCYLARGINYLPROLYLSERYLGLYCYLGLUTAMYLTRYTOPHYLLYSINE; ANTISENSE OLIGONUCLEOTIDE; ARGINYLARGINYLLYSYLARGINYLARGINYLARGININE; ARGINYLARGINYLPROLYLSERYLHISTIDYLALANYLARGININE; ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID 4C; ASPARAGINYLARGINYLPROLYLALANYLASPARAGINYLSERYLMETHIONINE; ASPARAGINYLGLYCYLARGININE; ASPARTYLPROLYLARGININE; ASPARTYLPROLYLARGINYLALANYLTHREONYLPROLYLGLYCYLSERINE; CYSTEINYLGLYCYLASPARAGINYLLYSYLARGINYLTHREONYLARGINYLGLYCYLCYSTEINE; CYTOTOXIC AGENT; DOXORUBICIN; DRUG CARRIER; GLUTAMINYLISOLEUCYLALANYLSERYLGLYCYLARGINYLTRYPTOPHYLLEUCINE; GLUTAMINYLVALYLISOLEUCYLLEUCYLALANYLSERYLGLYCYLARGINYLTRYPTOPHYLLEUCINE; LEUCYLTHREONYLVALYLSERYLPROLYLTRYPTOPHYLTYROSINE; LEUCYLVALYLARGINYLSERYLTHREONYLGLYCYLGLUTAMINYLPHENYLALANYLVALINE; LEUCYLVALYLSERYLPROLYLSERYLGLYCYLSERYLTRYPTOPHYLTHREONINE; LIPOSOME; LYSYLYCYSTEINYLCYSTEINYLTYROSYLSERYLLEUCINE; OLIGONUCLEOTIDE; PRODRUG; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SYNTHETIC PEPTIDE; SYNTHETIC SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; THREONYLSERYLPROLYLLEUCYLASPARAGINYLISOLEUCYLHISTIDYLASPARAGINYLGLYCYLGLUTA MINYLLYSYLLEUCINE; TUMOR CELL TARGETING PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; CANCER CELL; DRUG DELIVERY SYSTEM; DRUG SPECIFICITY; DRUG TARGETING; GENE DELIVERY SYSTEM; GENE THERAPY; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN TARGETING; RECEPTOR BINDING; REVIEW; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

EID: 0842312445     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2003.11.002     Document Type: Article

References (109)

1. Adessi, C., Soto, C., 2002. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. 9, 963-978.
2. Aina, O.H., Sroka, T.C., Chen, M.L., Lam, K.S., 2002. Therapeutic cancer targeting peptides. Biopolymers 66, 184-199.
3. Alaoui-Jamali, M.A., Qiang, H., 2003. The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery. Drug Resist. Updat. 6, 95-107.
4. Alitalo, K., Carmeliet, P., 2002. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1, 219-227.
5. Alizadeh, A.A., Ross, D.T., Perou, C.M., van de Rijn, M., 2001. Towards a novel classification of human malignancies based on gene expression patterns. J. Pathol. 195, 41-52.
6. Arap, W., Pasqualini, R., Ruoslahti, E., 1998. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-380.
7. Arap, W., Haedicke, W., Bernasconi, M., Kain, R., Rajotte, D., Krajewski, S., Ellerby, H.M., Bredesen, D.E., Pasqualini, R., Ruoslahti, E., 2002. Targeting the prostate for destruction through a vascular address. Proc. Natl. Acad. Sci. U.S.A. 99, 1527-1531.
8. Arap, W., Kolonin, M.G., Trepel, M., Lahdenranta, J., Cardo-Vila, M., Giordano, R.J., Mintz, P.J., Ardelt, P.U., Yao, V.J., Vidal, C.I., Chen, L., Flamm, A., Valtanen, H., Weavind, L.M., Hicks, M.E., Pollock, R.E., Botz, G.H., Bucana, C.D., Koivunen, E., Cahill, D., Troncoso, P., Baggerly, K.A., Pentz, R.D., Do, K.A., Logothetis, C.J., Pasqualini, R., 2002. Steps toward mapping the human vasculature by phage display. Nat. Med. 8, 121-127.
9. Arnt, C.R., Chiorean, M.V., Heldebrant, M.P., Gores, G.J., Kaufmann, S.H., 2002. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J. Biol. Chem. 277, 44236-44243.
10. Asai, T., Nagatsuka, M., Kuromi, K., Yamakawa, S., Kurohane, K., Ogino, K., Tanaka, M., Taki, T., Oku, N., 2002. Suppression of tumor growth by novel peptides homing to tumor-derived new blood vessels. FEBS Lett. 510, 206-210.
11. Assa-Munt, N., Jia, X., Laakkonen, P., Ruoslahti, E., 2001. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry 40, 2373-2378.
12. Bae, D.G., Gho, Y.S., Yoon, W.H., Chae, C.B., 2000. Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis. J. Biol. Chem. 275, 13588-13596.
13. Bauerschmitz, G.J., Lam, J.T., Kanerva, A., 2002. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res. 62, 1266-1270.
14. Beven, L., Castano, S., Dufourcq, J., Wieslander, A., Wroblewski, H., 2003. The antibiotic activity of cationic linear amphipathic peptides: lessons from the action of leucine/lysine copolymers on bacteria of the class Mollicutes. Eur. J. Biochem. 270, 2207-2217.
15. Binétruy-Tournaire, R., Demangel, C., Malavaud, B., Vassy, R., Rouyre, S., Kraemer, M., Plouet, J., Derbin, C., Perret, G., Mazie, J.C., 2000. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 19, 1525-1533.
16. Boehm, T., Folkman, J., Browder, T., O'Reilly, M.S., 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407.
17. Brignole, C., Pagnan, G., Marimpietri, D., Cosimo, E., Allen, T.M., Ponzoni, M., Pastorino, F., 2003. Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. Cancer Lett. 197, 231-235.
18. Browder, T., Butterfield, C.E., Kraling, B.M., Shi, B., Marshall, B., O'Reilly, M.S., Folkman, J., 2000. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878-1886.
19. Buhl, L., Szecsi, P.B., Gisselo, G.G., Schafer-Nielsen, C., 2002. Surface immunoglobulin on B lymphocytes as a potential target for specific peptide ligands in chronic lymphocytic leukaemia. Br. J. Haematol. 116, 549-554.
20. Burg, M.A., Pasqualini, R., Arap, W., Ruoslahti, E., Stallcup, W.B., 1999. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res. 59, 2869-2874.
21. Burg, M.A., Jensen-Pergakes, K., Gonzalez, A.M., Ravey, P., Baird, A., Larocca, D., 2002. Enhanced phagemid particle gene transfer in camptothecin-treated carcinoma cells. Cancer Res. 62, 977-981.
22. Campa, M.J., Serlin, S.B., Patz, Jr., E.F., 2002. Development of novel tumor imaging agents with phage-display combinatorial peptide libraries. Acad. Radiol. 9, 927-932.
23. Cattel, L., Ceruti, M., Dosio, F., 2003. From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori 89, 237-249.
24. Chen, Y., Xu, X., Hong, S., Chen, J., Liu, N., Underhill, C.B., Creswell, K., Zhang, L., 2001. RGD-Tachyplesin inhibits tumor growth. Cancer Res. 61, 2434-2438.
25. Cheng, J.Q., Jiang, X., Fraser, M., Li, M., Dan, H.C., Sun, M., Tsang, B.K., 2002. Role of X-linked inhibitor of apoptosis proteins in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist. Updat. 5, 131-146.
26. de Groot, F.M., Broxterman, H.J., Adams, H.P., van Vliet, A., Tesser, G.I., Elderkamp, Y.W., Schraa, A.J., Kok, R.J., Molema, G., Pinedo, H.M., Scheeren, H.W., 2002. Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug. Mol. Cancer Ther. 1, 901-911.
27. DeRisi, J., Penland, L., Brown, P.O., Bittner, M.L., Meltzer, P.S., Ray, M., Chen, Y., Su, Y.A., Trent, J.M., 1996. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat. Genet. 14, 457-460.
28. Dybwad, A., Lambin, P., Sioud, M., Zouali, M., 2003. Probing the specificity of human myeloma proteins with a random peptide phage library. Scand. J. Immunol. 57, 583-590.
29. Eliceiri, B.P., Cheresh, D.A., 2000. Role of alpha v integrins during angiogenesis. Cancer J. 6 (Suppl. 3), S245-S249.
30. Ellerby, H.M., Arap, W., Ellerby, L.M., Kain, R., Andrusiak, R., Rio, G.D., Krajewski, S., Lombardo, C.R., Rao, R., Ruoslahti, E., Bredesen, D.E., Pasqualini, R., 1999. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5, 1032-1038.
31. El-Mousawi, M., Tchistiakova, L., Yurchenko, L., Pietrzynski, G., Moreno, M., Stanimirovic, D., Ahmad, D., Alakhov, V., 2003. A VEGF high affinity receptor 1 specific peptide with antiangiogenic activity identified using a phage display peptide library. J Biol Chem., doi 10.1074/jbc. M308681200.
32. Essler, M., Ruoslahti, E., 2002. Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc. Natl. Acad. Sci. U.S.A. 99, 2252-2257.
33. Fahr, A., Muller, K., Nahde, T., Muller, R., Brusselbach, S., 2002. A new colloidal lipidic system for gene therapy. J. Liposome Res. 12, 37-44.
34. Fairbrother, W.J., Christinger, H.W., Cochran, A.G., 1998. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry 37, 17754-17764.
35. Fan, H., Duan, Y., Zhou, H., Li, W., Li, F., Guo, L., Roeske, R.W., 2002. Selection of peptide ligands binding to fibroblast growth factor receptor 1. IUBMB Life 54, 67-72.
36. Folkman, J., 2002. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29 (6 Suppl. 16), 15-18.
37. Fueyo, J., Alemany, R., Gomez-Manzano, C., 2003. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J. Natl. Cancer Inst. 95, 652-660.
38. Fukuda, M.N., Ohyama, C., Lowitz, K., Matsuo, O., Pasqualini, R., Ruoslahti, E., Fukuda, M., 2000. A peptide mimic of E-selectin ligand inhibits sialyl Lewis X-dependent lung colonization of tumor cells. Cancer Res. 60, 450-456.
39. Fulda, S., Debatin, K.M., 2003. Apoptosis pathways: turned on their heads? Drug Resist. Updat. 6, 1-3.
40. Gerlag, D.M., Borges, E., Tak, P.P., Ellerby, H.M., Bredesen, D.E., Pasqualini, R., Ruoslahti, E., Firestein, G.S., 2001. Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. Arthritis Res. 3, 357-361.
41. Gorski, A., Dabrowska, K., Switala-Jelen, K., Nowaczyk, M., Weber-Dabrowska, B., Boratynski, J., Wietrzyk, J., Opolski, A., 2003. New insights into the possible role of bacteriophages in host defense and disease. Med. Immunol. 2, 2.
42. Grifman, M., Trepel, M., Speece, P., Gilbert, L.B., Arap, W., Pasqualini, R., Weitzman, M.D., 2001. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol. Ther. 3, 964-975.
43. Grill, J., Van Beusechem, V.W., Van Der Valk, P., Dirven, C.M., Leonhart, A., Pherai, D.S., Haisma, H.J., Pinedo, H.M., Curiel, D.T., Gerritsen, W.R., 2001. Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin. Cancer Res. 7, 641-650.
44. Hartley, O., 2002. The use of phage display in the study of receptors and their ligands. J. Recept. Signal Transduct. Res. 22, 373-392.
45. Haubner, R., Wester, H.J., Weber, W.A., 2001. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61, 1781-1785.
46. Hetian, L., Ping, A., Shumei, S., Xiaoying, L., Luowen, H., Jian, W., Lin, M., Meisheng, L., Junshan, Y., Chengchao, S., 2002. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J. Biol. Chem. 277, 43137-43142.
47. Hong, F.D., Clayman, G.L., 2000. Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. Cancer Res. 60, 6551-6556.
48. Ivanenkov, V.V., Felici, F., Menon, A.G., 1999a. Uptake and intracellular fate of phage display vectors in mammalian cells. Biochim. Biophys. Acta 1448, 450-462.
49. Ivanenkov, V.V., Felici, F., Menon, A.G., 1999b. Targeted delivery of multivalent phage display vectors into mammalian cells. Biochim. Biophys Acta. 1448, 463-472.
50. Jain, S., Mishra, V., Singh, P., Dubey, P.K., Saraf, D.K., Vyas, S.P., 2003. RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int. J. Pharm. 261, 43-55.
51. Janssen, A.P., Schiffelers, R.M., ten Hagen, T.L., Koning, G.A., Schraa, A.J., Kok, R.J., Storm, G., Molema, G., 2003. Peptide-targeted PEG-liposomes in anti-angiogenic therapy. Int. J. Pharm. 254, 55-58.
52. Javadpour, M.M., Juban, M.M., Lo, W.C., Bishop, S.M., Alberty, J.B., Cowell, S.M., Becker, C.L., McLaughlin, M.L., 1996. De novo antimicrobial peptides with low mammalian cell toxicity. J. Med. Chem. 39, 3107-3113.
53. Jost, P.J., Harbottle, R.P., Knight, A., Miller, A.D., Coutelle, C., Schneider, H., 2001. A novel peptide, THALWHT, for the targeting of human airway epithelia. FEBS Lett. 489, 263-269.
54. Kanerva, A., Wang, M., Bauerschmitz, G.J., 2002. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther. 5, 695-704.
55. Karasseva, N.G., Glinsky, V.V., Chen, N.X., Komatireddy, R., Quinn, T.P., 2002. Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. J. Protein Chem. 21, 287-296.
56. Kay, B.K., Kurakin, A.V., Hyde-Deruyscher, R., 1998. From peptides to drugs via phage display. Drug Discov. Today 3, 370-377.
57. Kennel, S.J., Mirzadeh, S., Hurst, G.B., 2000. Labeling and distribution of linear peptides identified using in vivo phage display selection for tumors. Nucl. Med. Biol. 27, 815-825.
58. Koivunen, E., Wang, B., Ruoslahti, E., 1995. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology 13, 265-270.
59. Koivunen, E., Arap, W., Valtanen, H., 1999. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17, 768-774.
60. Kunath, K., Merdan, T., Hegener, O., Haberlein, H., Kissel, T., 2003. Integrin targeting using RGD-PEI conjugates for in vitro gene transfer. J. Gene Med. 5, 588-599.
61. Laakkonen, P., Porkka, K., Hoffman, J.A., Ruoslahti, E., 2002. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 8, 751-755.
62. Larocca, D., Kassner, P.D., Witte, A., Ladner, R.C., Pierce, G.F., Baird, A., 1999. Gene transfer to mammalian cells using genetically targeted filamentous bacteriophage. FASEB J. 13, 727-734.
63. Larocca, D., Burg, M.A., Jensen-Pergakes, K., Ravey, E.P., Gonzalez, A.M., Baird, A., 2002. Evolving phage vectors for cell targeted gene delivery. Curr. Pharm. Biotechnol. 3, 45-57.
64. Lee, J.H., Engler, J.A., Collawn, J.F., Moore, B.Az., 2001. Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur. J. Biochem. 268, 2004-2012.
65. Lee, L., Buckley, C., Blades, M.C., Panayi, G., George, A.J., Pitzalis, C., 2002. Identification of synovium-specific homing peptides by in vivo phage display selection. Arthritis Rheum. 46, 2109-2120.
66. Lowman, H.B., Chen, Y.M., Skelton, N.J., Mortensen, D.L., Tomlinson, E.E., Sadick, M.D., Robinson, I.C., Clark, R.G., 1998. Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions. Biochemistry 37, 8870-8878.
67. Lysik, M.A., Wu-Pong, S., 2003. Innovations in oligonucleotide drug delivery. J. Pharm. Sci. 92, 1559-1573.
68. Michon, I.N., Hauer, A.D., von der Thusen, J.H., Molenaar, T.J., van Berkel, T.J., Biessen, E.A., Kuiper, J., 2002. Targeting of peptides to restenotic vascular smooth muscle cells using phage display in vitro and in vivo. Biochim. Biophys. Acta 1591, 87-97.
69. Mier, W., Eritja, R., Mohammed, A., Haberkom, U., Eisenhut, M., 2003. Peptide-PNA conjugates: targeted transport of antisense therapeutics into tumors. Angew. Chem. Int. Ed. Engl. 42, 1968-1971.
70. Monaci, P., Urbanelli, L., Fontana, L., 2001. Phage as gene delivery vectors. Curr. Opin. Mol. Ther. 3, 159-169.
71. Müller, O.J., Kaul, F., Weitzman, M.D., Pasqualini, R., Arap, W., Kleinschmidt, J.A., Trepel, M., 2003. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat. Biotechnol. 21, 1040-1046.
72. Nielsen, U.B., Marks, J.D., 2000. Internalizing antibodies and targeted cancer therapy: direct selection from phage display libraries. Pharm. Sci. Technol. Today 3, 282-291.
73. Oku, N., Asai, T., Watanabe, K., 2002. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene 21, 2662-2669.
74. Opalinska, J.B., Gewirtz, A.M., 2002. Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1, 503-514.
75. Pan, W., Arnone, M., Kendall, M., Grafstrom, R.H., Seitz, S.P., Wasserman, Z.R., Albright, C.F., 2003. Identification of peptide substrates for human MMP-11 (stromelysin-3) using phage display. J. Biol. Chem. 278, 27820-27827.
76. Papo, N., Shahar, M., Eisenbach, L., Shai, Y., 2003. A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. J. Biol. Chem. 278, 21018-21023.
77. Pasqualini, R., Ruoslahti, E., 1996. Organ targeting in vivo using phage display peptide libraries. Nature 380, 364-366.
78. Pasqualini, R., Koivunen, E., Ruoslahti, E., 1997. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15, 542-546.
79. Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R.A., Shapiro, L.H., Arap, W., Ruoslahti, E., 2000. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60, 272-722.
80. Rasmussen, U.B., Schreiber, V., Schultz, H., Mischler, F., Schughart, K., 2002. Tumor cell-targeting by phage-displayed peptides. Cancer Gene Ther. 9, 606-612.
81. Renschler, M.F., Bhatt, R.R., Dower, W.J., Levy, R., 1994. Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 91, 3623-3627.
82. Romanov, V.I., 2003. Phage display selection and evaluation of cancer drug targets. Curr. Cancer Drug Targets 3, 119-129.
83. Romanov, V.I., Durand, D.B., Petrenko, V.A., 2001. Phage display selection of peptides that affect prostate carcinoma cells attachment and invasion. Prostate 47, 239-251.
84. Ryadnov, M.G., Degtyareva, O.V., Kashparov, I.A., Mitin, Y.V., 2003. Antimicrobial peptides containing arginine. Biochemistry (Mosc.) 68, 857-861.
85. Sadler, K., Tam, J.P., 2002. Rev. Mol. Biotechnol. 90, 195-229.
86. Salvesen, G.S., Duckett, C.S., 2002. IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell. Biol. 3, 401-410.
87. Schiffelers, R.M., Koning, G.A., ten Hagen, T.L., 2003. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. Control. Release 91, 115-122.
88. Shadidi, M., Sioud, M., 2003. Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB J. 17, 256-258.
89. Sioud, M., 2001. Nucleic acid enzymes as a novel generation of anti-gene agents. Curr. Mol. Med. 1, 575-588.
90. Sioud, M., 2003. Therapeutic siRNAs. Tr. Pharmacol. Sci.
91. Sioud, M., Forre, O., Dybwad, A., 1996. Selection of ligands for polyclonal antibodies from random peptide libraries: potential identification of (auto)antigens that may trigger B and T cell responses in autoimmune diseases. Clin. Immunol. Immunopathol. 79, 105-114.
92. Simeoni, F., Morris, M.C., Heitz, F., Divita, G., 2003. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res. 31, 2717-2724.
93. Sorensen, D.R., Leirdal, M., Sioud, M., 2003. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 327, 761-766.
94. Spear, M.A., Breakefield, X.O., Beltzer, J., Schuback, D., Weissleder, R., Pardo, F.S., Ladner, R., 2001. Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells. Cancer Gene Ther. 8, 506-511.
95. St. Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K.E., Montgomery, E., Lal, A., Riggins, G.J., Lengauer, C., Vogelstein, B., Kinzler, K.W., 2000. Genes expressed in human tumor endothelium. Science 289, 1197-1202.
96. Su, Z.F., Liu, G., Gupta, S., Zhu, Z., Rusckowski, M., Hnatowich, D.J., 2002. In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(v)beta(3) integrin for tumor imaging. Bioconjug. Chem. 13, 561-570.
97. Suh, W., Han, S.O., Yu, L., Kim, S.W., 2002. An angiogenic, endothelial-cell-targeted polymeric gene carrier. Mol. Ther. 6, 664-672.
98. Szecsi, P.B., Riise, E., Roslund, L.B., Engberg, J., Turesson, I., Buhl, L., Schafer-Nielsen, C., 1999. Identification of patient-specific peptides for detection of M-proteins and myeloma cells. Br. J. Haematol. 107, 357-364.
99. Takahashi, S., Mok, H., Parrott, M.B., Marini, III, F.C., Andreeff, M., Brenner, M.K., Barry, M.A., 2003. Selection of chronic lymphocytic leukemia binding peptides. Cancer Res. 63, 5213-5217.
100. Tamm, I., Trepel, M., Cardo-Vila, M., Sun, Y., Welsh, K., Cabezas, E., Swatterthwait, A., Arap, W., Reed, J.C., Pasqualini, R., 2003. Peptides targeting caspase inhibitors. J. Biol. Chem. 278, 14401-14405.
101. Tomar, R.S., Matta, H., Chaudhary, P.M., 2003. Use of adeno-associated viral vector for delivery of small interfering RNA. Oncogene 22, 5712-5715.
102. Tucker, G.C., 2003. Alpha v integrin inhibitors and cancer therapy. Curr. Opin. Investig. Drugs 4, 722-731.
103. Urbanelli, L., Ronchini, C., Fontana, L., Menard, S., Orlandi, R., Monaci, P., 2001. Targeted gene transduction of mammalian cells expressing the HER2/neu receptor by filamentous phage. J. Mol. Biol. 313, 965-976.
104. Van Hagen, P.M., Breeman, W.A., Bernard, H.F., 2000. Evaluation of a radiolabelled cyclic DTPA-RGD analogousue for tumour imaging and radionuclide therapy. Int. J. Cancer 90, 186-198.
105. Wu, P., Leinonen, J., Koivunen, E., Lankinen, H., Stenman, U.H., 2000. Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur. J. Biochem. 267, 6212-6220.
106. Yamamoto, Y., Tsutsumi, Y., Mayumi, T., 2002. Molecular design of bioconjugated cell adhesion peptides with a water-soluble polymeric modifier for enhancement of antimetastatic effect. Curr. Drug Targets 3, 123-130.
107. Yu, D., Hung, M.C., 2000. Role of erbB2 in breast cancer chemosensitivity. Bioessays 22, 673-680.
108. Zhang, J., Spring, H., Schwab, M., 2001. Neuroblastoma tumor cell-binding peptides identified through random peptide phage display. Cancer Lett. 171, 153-164.
109. Zitzmann, S., Ehemann, V., Schwab, M., 2002. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 62, 5139-5143.